

Index

Note: To allow faster and more comprehensive searches, an electronic version of the index will be available on our website (www.fanconi.org).

- acute myelogenous leukemia (AML), 14, 16-18, 38-39, 42-43, 45-51, 53, 60, 71, 176, 198, 228, 270, 289, 291-293, 298, 300, 304-305, 373, 382
- adenoma, see *hepatic*
- adrenal insufficiency, 157, 159, 161
- adrenocorticotrophic hormone (ACTH), 150, 161-162
- adult FA patient, 295-306; gynecologic and fertility issues, 300; bone marrow transplant, 299; psychosocial issues, 302; solid tumors in, 298-299; transition from pediatric to adult-oriented care, 300
- agranulocytosis, 66
- alanine transaminase (ALT), 65-66, 86, 88-91, 382
- albumin, 90
- alcohol, risks from use, 2, 4, 14, 90, 93, 205-206, 218, 227, 251, 271-274, 283, 293, 298, 302, 343, 345
- Alexander Graham Bell Association for the Deaf and Hard of Hearing, 192
- alkaline phosphatase (ALP), 90, 382
- allergies, 226
- alternative medicine, 95
- American Academy of Audiology, 193, 195
- American Academy of Otolaryngology, 193
- American Diabetes Association, 377
- American Society of Blood and Marrow Transplantation, 245, 255
- American Speech-Language-Hearing Association, 193
- amniocentesis, 18, 324, 371
- anal atresia, see *anus*

- androgens, 14, 53-56, 58-60, 62, 67, 72, 87-88, 91, 97, 129, 147, 153, 169, 171, 223, 226, 238, 290, 336, 376, 379, 382; androgen-responsive “acquired” aplastic anemia, 17; danazol, 55-56, 67, 72, 354; effect of androgens on: endocrine function, 169, glucose metabolism, 151, 154, growth, 54, insulin resistance 132, 153-154, 156, 167, 170-171, 250, lipids, 132, liver, 54, 376, 87-91, masculinizing side effects of, 55; menses, 381; oxymetholone, 54-56, 67; pregnancy, use during, 129; risks and side effects of, 54; transplant, use prior to, 59-61
- anemia, 1, 3, 5-6, 10, 14, 17, 21-27, 33, 35, 41-45, 48-49, 55, 57, 60-62, 66, 68-74, 96-99, 121, 123, 133, 139-141, 144, 167, 171-173, 175-177, 179, 192, 194-196, 198, 202-203, 217, 219, 221, 223, 225, 230, 239-240, 242-246, 255-259, 267-272, 282, 284-288, 294-295, 298, 300, 304-305, 307, 310, 312, 314-316, 319, 327-331, 333, 336, 341, 344, 350-352, 367-369, 375, 382-383, 386, 394-398; aplastic, 14, 17, 33, 43, 48-49, 55, 72-73, 98, 177, 221, 223, 225, 230, 239, 243, 245, 285, 298, 382-383
- anesthesia, see *pain*
- anus, 75, 77, 308, 382, anal atresia, 102; anorectal malformations, 75-77; ectopic, 19; imperforate, 20
- aplastic anemia, see *anemia*
- appetite, 74, 83-85, 96, 150; glucocorticoids, effect on, 170; stimulants, 85, 88, 96, 99; supplemental feeding, 83-85, 91, 95
- arm lengthening, see *forearm lengthening*
- arthritis, 66, 300
- aseptic necrosis of bone or joints, see *avascular necrosis*
- aspartate transaminase (AST), 86, 88-91, 383
- asthma, 228
- autosomal recessive inheritance, see *genetic counseling*
- avascular necrosis, 56, 250
- azoospermic, 300
- bacteremia, 379
- beta cell dysfunction, 171
- biliary, 90, bilirubin, 88, 90, 369
- bladder abnormalities, 228, 369

- bleeding, 43, 56-57, 60, 63-64, 67, 77, 79, 84, 88, 91, 95, 123, 129, 133-135, 163, 188, 203, 213, 216, 228, 353; from duodenal intubation, 79; from fish oil (omega-3 fatty acid), 95; from ginkgo, 228; from hepatic adenoma, 56, 88; excessive menstrual bleeding, 123, 129, 133; mucosal, 67, 133; oral, 203, 213, 215-16; risk from drugs such as aspirin or ibuprofen, 67; side effect of cyclosporine A/tacrolimus, 233; menstrual, 123, 129, 133
- blind loop syndrome, 77
- blood counts, 45-49, 51-54, 59, 107, 169, 227, 297, 354, 369, 376; post-transplant, 374; to monitor bone marrow failure, 45, 49-52
- body mass index, 81-82, 124, 150, 153, 383
- bone age, 147-148, 163, 169
- bone marrow, 6, 11, 13, 16-18, 21, 26-27, 32-33, 35, 37-40, 42-54, 56-59, 61-63, 66-73, 80, 96, 98, 124, 133, 142, 154, 172, 174, 177-178, 188, 198, 202, 212, 215-216, 222-223, 225, 228-230, 238-244, 250, 255-258, 261-263, 266, 268-270, 273, 279-280, 284-286, 290-291, 294, 296, 299, 304-305, 315-316, 323, 353-354, 362, 364-367, 369, 372-373, 379, 382-390, 392; aplasia, 298, 373; aspiration, biopsy, 45-52, 57, 198, 237, 369, 373; cellularity, 45-46, 49, 53; clinical monitoring and management of failure, 49-52, 373; clonal abnormalities, see *clones*, *cytogenetic clonal abnormalities*; dysfunction, 43-52, 215-216; dysplasia, 45-46, 50, see also *myelodysplasia*; examination, 46, 49-51, 68, 374; onset of anemia, 61-62, 315; severity of failure, 49; suppression of, secondary to H2-antagonists, 80; suppression of, 51; transplant, see *transplant*; treatment options for failure, 52-61, 259-262
- bone mineral density, see *osteopenia*, *osteoporosis*
- bowel, 78-80, 391; antegrade continence enema (ACE) 78; constipation, 78-79, 234; encopresis, 78, 403, 407; fecal incontinence, 78; malabsorption, 82; obstruction, 80; small bowel overgrowth, 78-79
- breast cancer susceptibility genes, 319
- bronchitis, 228
- BUN (blood urea nitrogen test), 254
- Busulfan, 177-178, 223, 239, 384
- café au lait* spots, 17, 101, 228, 384
- cancer, 2-3, 5, 7-8, 14, 16, 18, 22, 24, 26, 34, 37-38, 41-44, 69-73, 77, 85-86, 90, 94-98, 123-132, 135, 139-142, 160, 171-173, 175-176, 195-196, 198-202, 205-207, 209, 211, 213, 215-218, 220, 224, 227, 237-238, 241-243,

- 245, 255-258, 261-263, 265, 268, 270-273, 275, 277-278, 281, 283-294, 297-299, 304-308, 313, 315, 319-323, 326, 328-332, 343-345, 350-351, 353, 369-370, 372, 378-383, 385, 389-391, 394, 396, 399-400; family history of, 84, 308, 369; risk of, 94, 321-323, 326, 330, 370, 404; secondary, 300-301; surveillance for, 3, 14, 128, 251, 275-276, 297-298, 313, 372, 378-380
- cancer, types of, acute lymphocytic (lymphoid) leukemia, 145; acute myelogenous leukemia (AML), 14, 16-18, 38-39, 42-43, 45-51, 53, 60, 71, 176, 198, 228, 270, 289, 291-293, 298, 300, 304-305, 373, 382; astrocytoma, 314; bladder, 289; brain, 20, 287-293; breast, 2, 7, 123, 128-129, 131, 135-136-224, 287-291, 299, 308, 319-323, 379-380; breast, male, 308, 319, 321; cervical, 20, 125-127, 136; colon, 289; dermatofibroma, 289; esophageal, 18, 20, 86-87, 204, 275, 287; gastrointestinal, 86, 308; genitourinary, 273-274; gynecological, 2, 18, 128, 136, 160, 273, 380-381; head and neck squamous cell carcinoma, *see head and neck squamous cell carcinoma*; human papillomavirus (HPV)- associated, 18, 124-127, 136- 238, 271-274, 293, 298, 379; kidney, *see cancer; renal*; liver (hepatocellular), 18, 54, 56, 87-88, 90, 93, 287, 290-291; lung, 289-291; lymphoma, 45, 289; medulloblastoma, 16, 20, 34, 314; melanoma, 196, 199, 201, 228, 320; neuroblastoma, 20, 287, 290-293; osteosarcoma, 289; ovarian, 7-8, 127, 132, 298, 308, 319-323; pancreatic, 8, 319, 322; prostate, 308, 319, 321-322; renal, 287, 290; retinoblastoma, 20, 273, 289; skin, 196, 198-208, 248, 254, 380; stomach, 289-291; vaginal, 16, 20, 125, 379; vulvar, 16, 20, 125-127, 136, 228, 287, 298, 379; Wilms tumor, 16, 17, 20, 34, 287, 292-293, 314, *see also renal*
- carcinogens, to avoid, 4, 271, 293
- cardiac, 62-64, 66, 76, 248, 380, 392, arrhythmias, 63, 66; cardiac iron toxicity, 62-66; cardiac siderosis, 62; cardiovascular disease, 86, 131-132, 380; function, 62, 65-66; toxicity, 63, 65-66; transplant, late complication, 248, 252
- cardiopulmonary, congenital defects, 19
- cardiovascular, 86, 131-132, 173, 256-257, 380, vascular disease, 380
- carpometacarpal 103, 106
- carriers, 2, 140-141, 299, 307-308, 312, 318-323, 330, 339, 384, 391, cancer risk in, 2, 15, 299, 307, 319-323; risk of FA in each pregnancy, 310; testing, 316-319
- Center for International Blood and Marrow Transplant Research, 222, 239, 245, 255, 384

- Centers of Excellence, 226
- central venous catheter, 83
- cervical esophagus, 275
- cetuximab, see *erbitux*
- chest x-ray, 276
- Children's Oncology Group, 169, 245, 255
- chimerism, 250
- cholestasis, 91-92, 249, 281
- cholestatic jaundice, 88
- chorionic villus sampling, 18, 324
- chromosomal breakage or fragility test, 12, 29-32, 101, 324, 371; confirmatory FA diagnosis prior to HSCT, 59-60, 229, 237; see also *diagnosis of FA*
- cirrhosis, 62-63, 88, 92-93, 375
- cisplatin, 280
- clinical management checklist, 367
- clinical trials, 3, 94, 98, 202, 256, 259, 265, 267, 279, 375
- clones, 39, 42, 47-48, 51, 270, 305, cytogenetic clonal abnormalities, 51; significance of clone, 37-40, 47-50
- colony stimulating factors, see *hematopoietic growth factors*
- colposcopy, 127, 379, 385
- comparative genomic hybridization (CGH), 36, 47, 312
- Complementary and Alternative Medicine of the National Institutes of Health, Office of, 95
- complementation groups, , 11, 23, 29, 146, 385; genotype-phenotype correlations, 2, 12, 15-17, 34; relative frequency of, 10; testing for, 11-12
- consanguinity, 369
- constipation, 67, 78-79
- contraception, hormonal, 124, 164, 379
- corticosteroids, 147, 153, 166, 375
- cortisol sufficiency, see *endocrine system*

- cough, 77
- creatinine, 369
- cryptorchidism, 161, 164
- cryptosporidia antigen, 79
- cytokine therapy, see *colony stimulating factors*
- cytopenia, 43, 45-46, 49, 224, 281, 316, 385; androgen treatment for, 53-56
- D2 Western Blot, see *FANCD2 Western Blot*
- danazol, see *androgens*
- deafness, 190, 193
- dental 8, 191, 203-204, 206-209, 211-213, 216-218, 228, 238, 248, 257, 274-275, 282, 299, 378, caries due to chronic GvHD, 204; gingivitis, 203, non-alcohol mouthwash, use of, 205-206; oral hygiene, 203; orthodontic treatment, 211; periodontitis, 203; pre-transplant examination, 215-216; surveillance for oral cancer, 209-210
- dermatology, 397; basal cell carcinoma, 196, 198-199; *café au lait* spots, 197; cutaneous (skin) GvHD, 200-201; darkening of skin, 197; dermatology exams post-transplant, 196; dry skin, 246; fibroblasts, 317; hyperpigmentation, 17; hypopigmentation, 17; melanoma, 199-200, 201, 228, 320; nevi, 199, 228, 248, 254, 380; rash, 161, 231, 233-234, 280; squamous cell carcinoma, 198-199; sun exposure effect on, 196, 197, 200; Sweet's syndrome, 196-198, 392, 406, 418
- diabetes, 63, 86, 93, 144, 153-154, 156, 160, 169, 172, 204, 206, 250, 256, 300, 377, 381, 388; abnormal glucose or insulin metabolism in, 153-155; adult care for, 167; complication of obesity, 154; insulin therapy for during HSCT, 155; insulinemia, 155; post-transplant, 246, 250; risk of metabolic syndrome, 156; treatment of, 155
- diagnosis of FA, 3-14, 17-18, 27, 29, 32, 37, 44-45, 53, 75-76, 197-198, 291, 297-298, 313, 333, 335, 346, 350, 362; examples of anomalies, 19-20; index of suspicion, 17-20; indications for testing, 19-20; laboratory tests to diagnose, 27-40; testing siblings, see *siblings*
- diarrhea, 74, 78-79, 82, 84, 91, 228, 376
- diet, 85-86, 90-91, 95, 156, 200, 211, 251, 377, dietary record, 82, counseling, 80, 82-83, 86; dietary supplements, 83; nutrition, supplemental, 83-85, 91, 95; nutrition, see *nutrition*; obesity, overweight, see *obesity, overweight*;

- underweight, 82, 86, 147, 150, 406, 409, 415, 420-421, weight loss diet, 85-86
- DNA damage response pathway, 6-9
- drugs, see *medications*
- duodenal, 75, 77, 79, 96, 226, 386; duodenal atresia, 75, 77, 226; duodenal intubation, 79
- DXA scan, see *osteopenia, osteoporosis*
- dyslipidemia, 156, 250, 386
- dysphagia, 210, 275, 279
- ear, 179-181, 183-184, 186-192, 195, 210, 370, 376, absent ear canal (aural atresia), 181, 183, 188; anatomy and function of, 179-181; cochlea, 180-181, 190; ear canal, 180-181, 183, 187-190; ear malformations, 183; eardrum, 179-181, 183-184, 188-189, 192, 376; inner ear, 180; middle ear, 180; outer ear, 179
- ear and hearing abnormalities in FA, 183, 191
- education, 128, 184-186, 194-196, 245, 258, 297, 301, 303-304, 334, 342, 347, 376
- elbow, 100, 113, 116
- encopresis, 78
- endocrine system, 3, 144, 250, 386; androgen use, 147-148, 153-154, 157, 169; effect of, see *androgens*; bone mineral density, see *osteopenia, osteoporosis*; cortisol sufficiency, 161; diabetes, see *diabetes*; dyslipidemia, see *dyslipidemia*; endocrine issues in adults, 167; endocrine screening, 149, 407; endocrinopathies in children and adolescents, 407; glucose abnormalities, see *glucose abnormalities*; growth hormone deficiency, see *growth*; height, see *height*; hematopoietic stem cell transplant (HSCT), 169-170; hyperglycemia, see *hyperglycemia*; hypothyroidism, see *thyroid*; insulin, abnormal metabolism of, see *insulin*; medications and treatments that affect endocrine function, 169-170; multiple hormonal deficiencies, effect on pituitary-hypothalamus, 161-162; multiple transfusion therapy, effect on, 169; puberty, effect on, see *puberty*
- endometrium, 135
- endoscopy, 80, 84, 91
- epiphyseal closure, epiphyses, 54, 169

- erbitux, 280-281, 299
- erythrocyte sedimentation rate, 79
- erythroplakia, 386
- esophageal, 18, 75-76, 86-87, 96, 167, 204, 217, 275, 279, 286-287, 386;
 atresia, 75-77, 102; bleeding, 77; gastroesophageal reflux, see *reflux*; reflux,
 see *reflux*
- esophagus, 75-77, 87, 273, 275, 279, 290-291, 386, 392, 405, 408, cervical,
 275, 405
- ethnic background, examples of FA populations, 308, 311
- European Fanconi Anemia Research Group, 41, 329
- European Group for Blood and Marrow Transplantation (EBMT), 245
- exercise, 86, 156, 173, 251, 348
- eyes, 17, 88, 248, 345, 353, dry, 233, 246, 248, 374; epicanthal folds, 19;
 keratoconjunctivitis, 248; Sicca Syndrome, 246, 248
- FANCC IVS4*, 15-17, 33, 34, 146, 309, 315
- FANCD2* Western Blot, 12, 370
- fecal incontinence, 78
- fertility, infertility, 18, 124, 129-131, 135, 144, 164, 240, 300, 308, 323, 353,
 373, 379, 381 389; adult, 300; affected by HSCT, 231, 246, preservation,
 130-131, 164, 325
- fever, 64, 67, 197
- fibroblasts, 11, 14, 18, 32, 317, 368
- fibroids, endometrial, 133
- finger, index, 102, 105-109, 116, 121, 391
- flow cytometry, 11, 41, 368, 387
- fluid retention, 234
- fluorescent *in situ* hybridization (FISH), 38-40, 47
- fluoride treatment, 205, 206, 282
- folate deficiency, 83
- forearm lengthening, 119; distraction osteogenesis, 119; wrist fusion, 7, 119-
 120

- Founder effect or mutation, 6, 17, 342; different founder populations, 309
- fructosamine levels, 154
- FSH (follicle-stimulating hormone), 150, 163, 250, 254, 387
- galactorrhea, 170
- gallbladder disease, 78
- gastrogesophageal reflux (GER), see *reflux*
- gastrointestinal, 65-66, 74-75, 77-81, 84, 86, 91, 96-97, 134, 197, 240, 249, 308, 367, 376, 387; anal atresia, see *anus*; appetite stimulants, see *underweight*; duodenal atresia, see *duodenal*; esophageal atresia, 75-76, 96, 386, 409, gastric emptying, 77-78, 80-81, 85; gastritis, 80; gastroesophageal reflux, see *reflux*; gastrointestinal symptoms, 78-81; gastrointestinal tract anatomic abnormalities, 75-78; liver disease, see *hepatic*; nutrition as therapy, see *medications*; nutrition, supplemental, see *nutrition*; obesity and overweight, see *obesity and overweight*; peptic disorders, 80, 409, 416; tracheoesophageal fistula, see *tracheoesophageal fistula*
- gastrostomy tube, 83-84, 91
- genes 1-2, 6-8, 10-12, 16-17, 28, 31, 33-37, 44, 128, 132, 238, 241, 260-261, 264-266, 274, 290, 292-293, 308, 311-316, 318-319, 322, 327-328, 354, 366, 385, 388-389, 393, and gene products (proteins), 8, 10; *FANCA*, 6-8, 12, 16, 28, 34, 36, 42, 44, 164, 176, 265-266, 286, 305, 312-313, 315-316, 318, 327-328, 385; *FANCB*, 13, 25, 310, 385; *FANCC*, 6, 16, 24, 33, 42, 44, 146, 164, 265, 269, 313, 315-316, 322-323, 327; *FANCD1 (BRCA2)*, 8; *FANCD2*, 8, 12, 23, 33, 316, 328, 370; *FANCE*, 8; *FANCF*, 25, 312; *FANCGXRCC9*, 8; *FANCI (KIAA1794)*, 8; *FANCI (BACH1, BRIP1)*, 8; *FANCL (PHF9/POG)*, 8; *FANCM (hef)*, 8; *FANCN (PALB2)*, 8, *FANCO (RAD51C)*, 8, *FANCP (SLX4)*, 8, *FANCO (ERCC4)*, 8
- gene therapy, 3, 238, 259-261, 264-270, 362, 371, 387, 391; stem cell gene therapy, 264-266; stem cell therapy, 262-264
- genetic counseling, 3, 13, 15, 33, 59, 307, 318, 326, 370-371; autosomal recessive inheritance, 7, 9, 310, 317; genetic testing, 311-313, see also *mutation analysis* and *complementation groups*; mode of inheritance, 310-311; reproductive issues, 323-324
- genital warts, 124-125, 127, 274
- genotype-phenotype correlations, see *complementation groups*
- giardia antigen, 79

ginkgo, 228

glomerular filtration rate (GFR), 237

glucocorticoids, 160, 165, 171

glucose abnormalities, 153-155; in adults, 156, 167; during or post-HSCT, 169, 234; glucose intolerance assessment and monitoring, 154; incidence of in FA, 153; medications known to alter glucose metabolism, 155

gonads, 55, 130; Cytosan, effect on, 170; gonadal function, 149, gonadal abnormalities, 19, 63, 124, 130, 144, 148-149, 152, 161-164, 166-168, 170; hypogonadism, see *gonadal abnormalities*, 63, 124, 144, 148, 161-164, 166-168, 170-171, 176; effect of iron overload on, 149, 164; fertility, 164; HSCT effect on, 246, 250, 374; puberty, 162-163

graft-versus-host disease, 18, 53, 62, 91, 98, 126, 134, 140, 178, 200, 202, 240-241, 246, 248, 256-257, 263, 273, 285, 297, 387

grieving process, 349, 352-354, 357, 359-360, 366; and the physician's role, 361-366; physical changes due to, 359

growth, 45, 54, 57, 62-63, 74, 76, 81-83, 85, 90, 96, 99, 101, 111, 114, 118-119, 124, 144-149, 153, 157-161, 163, 166, 168-169, 171-178, 188, 200, 223, 229, 238, 245, 248, 250, 254, 256-257, 263-265, 280, 286, 342-343, 370, 377, 387, 390; androgen therapy effect on, 147, 148, 169; cortisol sufficiency, 149; hemoglobin level necessary for, 149, 154; hormone deficiency, 145; hormone, screening for, 149; iron overload, 153; pubertal delay, effect on, 153; radiation, effect on, 147, 159, 162, 169-171; rate and bone maturation, 147-148

growth plate, see *epiphyseal closure*

gynecologic and fertility issues in females, 123-137; cancer, see *cancer* for specific type; cervical cytology testing, 127, 136; fertility, see *fertility*; genital tract malformations, 164; gynecologic cancer, see *cancer, types of, gynecological*; gynecological issues related to HSCT, 133-135; human papillomavirus, see *cancer, types of, HPV-associated*; vaccination/immunization; mammograms, see *mammography*; menopause, see *menopause*; menses, 381; osteoporosis, see *osteopenia/osteoporosis*; pregnancy, see *pregnancy*; puberty, see *puberty*; uterine polyps, 410, vulvar cancer, 16, 20, 125-127, 136, 287, 298, 379

H2-antagonists, 80

hair, 163, 181, 200-201, facial, 54; pubic, 163, 166; scalp, 54

- hand and arm differences, 99-122
- head and neck squamous cell carcinoma (HNSCC), 16, 18, 71, 206, 217, 243, 284-286, 271-282, 291, 293, 299, 305, 378; age of presentation, 272, 275; chemotherapy treatment of, 280-282; diagnosis and evaluation, 275-276; frequency of in FA, 272-273; human papillomavirus, 272, see *vaccination/immunizations*; testing for FA in, 272; prevention of, 273-275; radiation treatment of, 278-279; surgical treatment of, 278; surveillance for, 275-276; tobacco and alcohol use risks, see *smoking; alcohol*; T-stage, 276
- hearing and ear abnormalities, 179, 191; hearing and ear screening, 185
- hearing loss, 179, 181-195, 248, 370, 376, amplification systems, 179, 186-187, 192, 376; diagnostic tests, 182, 185; early identification and intervention for, 185-186; iron chelator, possible effect of, 192; surgical management of, 188-190; types of, 181-183; useful resources for, 192-194
- heart, see *cardiac*
- heartburn, 84
- height, 81-83, 144-148, 158, 160-163, 165-167, 169-170, 174, 176, 248, 377, 383; adult height, estimates of, 146, 147, 148, 160; androgen use, effect on, 147, 169; birth weight, effect on, 146; caloric intake, effect on, 147; early or delayed puberty, effect on, treatment for, 147-148, 162, 163; height prediction based on bone maturation, 147-148; hormone deficiencies, effect on, 145-146; parental height, 146; short stature, 17, 19, 81, 130, 144, 145-147
- hematology, 5, 26, 42, 73, 96, 250, 304, 397; clinical monitoring of bone marrow failure, 49-52, see also *bone marrow*; management guidelines for bone marrow failure, 58-61 45-48, see also *bone marrow*; significance of clonal abnormalities, see *clones, cytogenetic clonal abnormalities*; supportive care, for severe marrow failure, 61-68; treatment options for bone marrow failure, 52-58, see also *bone marrow*
- hematopoietic growth factor, 223, 229, 238
- hematopoietic stem cell transplant, see *transplant*
- hemochromatosis, 93, 247, see also *iron overload*
- hemoglobin, 45, 54-55, 57, 60-62, 73, 149, 154, 224, 240, 388; as indicator for transplant, 224; effects of high altitude on, 61; fetal hemoglobin, 45, 154; glycosylated hemoglobin, 149, 154; monitoring of, 61; response to androgens, 54-55, 60; response to cytokines, 57; response to transfusions, 60-62

hepatic, 56, 62-64, 66, 74, 87, 89, 97-98, 249, 369, 375-376, 387; adenomas, 54, 56, 87, 88, 287, 291; androgens, effect on liver, see *androgens*; chronic hepatic GvHD of liver, 91-92, 249; cirrhosis, see *cirrhosis*; fatty infiltration of the liver, 93; hepatic fibrosis, 62, 63, 65; hepatic sinusoids, 87-88; hepatitis, 63, 90, 91, 93, 237; hepatocellular carcinoma, see *cancer, liver (hepatocellular)*; hepatoma, see *cancer, liver (hepatocellular)*; HSCT late effects, liver complications of, 249; iron overload, see *iron overload*; liver biopsy, 56, 63, 88, 89, 90, 92, 93, 249, 253; liver enzymes, 66, 86, 87, 88, 90, 91, 92, 237, 369, 374, 376; liver function and function tests, 56, 88, 134, 228, 253; liver transaminases, 56, 88, 89; liver tumor, see *cancer, liver (hepatocellular)*; peliosis hepatis, 54, 87-88

herbal remedies, 226; see also *vitamins, minerals, and herbal remedies*

heterozygote, 8

hip, dislocation, congenital, 54, 87-88

human papillomavirus immunization, see *vaccinations/immunizations*

humerus, 113

hydrogen breath test, 79

hyperglycemia, 154, 156, 171, 237

hyperlipidemia, see *dyslipidemia*

hypertension, 175, 223, 237, 256; androgen use, side effect of, 54; late effect of transplant, 237

hypertransaminasemia, 88

hypogenitalia, 19

hypogonadism, see *gonads, gonadal function*

hypopharynx, 210, 275, see also *head and neck squamous cell carcinoma*

hypospadias, 164

hypothalamus, 158, 162, 171

hypothyroidism, see *thyroid*

immunizations, see *vaccinations/immunizations*

immunoglobulin, 216

Individuals with Disabilities Education Act (IDEA), 185, 194-195, 267, 376

infections, 18, 43, 53, 56-57, 67-68, 78, 80, 84, 91, 124, 140, 189, 192, 203,

- 212-213, 216, 223, 228, 236, 239, 241, 251, 264, 278, 298, 353, 369, 382, 390; adenovirus, 260; alternate donor HSCT, risks and timing of infections after, 235; bacterial, 55, 56, 215, 233; cytomegalovirus (CMV), 62, 215, 220, 237, 375; Epstein-Barr virus (EBV), 11, 272; fungal, 68, 80, 215, 374; gastrostomy tubes, local infection from, 68, 80, 215, 374; giardia antigen, 79; hepatitis, chronic viral, 91; herpes or herpes simplex virus (HSV), 214, 215; HIV, 85, 237; infectious disease prophylaxis post-HSCT, 235; opportunistic, 78, 79, 223, 236, 374; ova and parasites, 82; prevention strategies, 136, 216, 235; protozoal, 374; systemic, 221, 223; urinary tract, 78, 369; varicella zoster virus (VZV), 90, 215; viral, 53, 55, 215, 264, 374; yeast, 215, 235, 374; *Yersinia enterocolitica*, 64, 65
- infertility, see *fertility*
- insulin, 86, 132, 144, 150, 153-154, 156, 167, 170-172, 250, 257, 377, abnormal lipid profile associated with insulin resistance, 156; abnormal metabolism of, 144, 153-154, 156; insulin-like growth factor I, 148, 149, 158, 254; hyperinsulinemia, 155, 171; screening for insulin levels, 86, 149, 154, 250; treatment of diabetes with, 155
- insurance, problems, 225, 226; insurance approval prior to donor search, 229
- International Fanconi Anemia Registry (IFAR), 24, 42, 44, 47, 69-70, 96, 171, 175, 256, 295, 304, 316, 319, 327, 329
- in vitro* fertilization, 221, 240, 324, 337, 389
- iron deficiency, 44
- iron overload, 2, 14, 58, 62-66, 73, 90, 92-94, 98, 153, 169, 247, 249, 296, 375, 381; chelation therapy, 63-64, 94, 238; clinical complications of, 63-64; effect of chelator on auditory function, 192, 376; effect of on endocrine function, 153, 169; iron supplements, risk of, 93, 95; management of, 64-66, 296; post-transplant, assessment and treatment of, 246, 247, 249, 252, 253, 296; transfusions, effect of on, 2, 14, 58, 62, 64, 90, 92-93, 153, 169, 375, 381
- iron supplements, 226
- irradiated blood, 62
- IVS4, see *FANCC IVS4*
- jejunum, 20
- kidney, 76, 101, 226, 236, 249, 282, 287, 290, 315, 369-370, 379, 391, see also *renal system*; absent, horseshoe, hypoplastic or dysplastic, 19, 369

- laryngoscopy, 283
- larynx, 210, 271, 275, 278-279, see also *head and neck squamous cell carcinoma*
- late effects of transplant, see *transplant, late effects*
- learning disabilities, 183-185, 227, 341-342
- leukoplakia, 389
- lipids, see *dyslipidemia*,
- liver, see *hepatic*
- lungs, 84, 197
- macrocytic red cells or macrocytosis, 17, 44-45
- magnesium, 166, 280
- malabsorption, 82
- malignancy, see *cancer* or specific type of cancer
- mammography, 128-129, 299, 379
- medications, 4, 56, 67, 80, 85, 90, 94, 127, 133, 175, 181, 199, 228, 232, 235, 344, 366, 371-372, 376, 386; antibiotics, 55, 68, 84, 181, 192, 198, 206, 215, 216, 236, 376; delayed gastric emptying, possibly caused by, 78; diarrhea, possibly caused by, 79, 228, 231, 232, 233, 234, 282; hearing loss, ototoxic drugs that may cause, 181, 192, 376; hepatotoxic drugs, 90; polypharmacy, 371; that inhibit platelet function, 67, 95
- menopause, 14, 123, 129, 131-133, 135, 143, 164, 167, 298, 300, 375, 379-381; hormone replacement therapy, 132, 136, 148; health risks, 131-132, 380; premature, 14, 19, 123, 129, 131-132, 135, 164, 167, 246, 298, 300, 375, 379, 380
- menses, 381
- mesenchymal cells, 263-264, 266
- metabolic syndrome, 86, 151, 156, 167, 171
- metacarpal, 19, 103-106, 108, 110, 118
- microcephaly, 8, 101
- micrognathia, 213
- midline defect, 161
- minerals, see *vitamins, minerals, and herbal remedies*

- mosaicism, 13, 15, 18, 30-32, 52, 195, 290, 294, 298, 304, 317, 389
 mouth sores, 214, 231, 233
 mucositis, 280-281
 mutation, 1, 7, 12, 14-15, 18, 23, 27-28, 30-31, 33-34, 36, 41-42, 51, 69, 128, 140-141, 146, 164, 238, 261, 264-265, 273, 286, 292, 299, 305, 308, 311-312, 314-319, 321-331, 371, 388-389, 391; analysis, effect on height, 146; high-risk mutations, 16-17; null 16, 34, 35
 myelodysplasia, myelodysplastic syndrome (MDS), 14-18, 37-39, 43-53, 60-61, 198, 220-225, 228-230, 238, 298, 371, 373; clonal abnormalities, 37-39, 45, 50, 57, significance of, 17; hematological care for, 51; HSCT treatment for, 60-61; indication to test for FA, 17
 nails, 110
 nasogastric tube, 83, 85
 nasojejunal tube, 83, 84
 nasopharynx, 210, 275
 National Comprehensive Cancer Network, 320
 National Institute on Deafness and Other Communication Disorders Information Clearinghouse, 193
 National Marrow Donor Program (NMDP), 59, 222, 225, 228-229, 241, 390
 nausea, 74, 78-81, 134, 347, 363, 376
 neurological, 248, 341; neurocognitive issues, 381; neuropsychology evaluation, 248
 neutropenia, 43, 45, 57, 64, 66-67, 192, 235, 241, 281, 390; neutropenic, 63, 211
 neutrophil count, 56-57, 224, 239, 382; absolute neutrophil count, 57, 224, 239, 382
 North American Survey (NAS), 288, 295
 novel hematopoietic stem cell treatment options, 259-267
 nutrition, 83, 94, 144, 147-148, 150, 169, 173, 249, 376, 398-399; diet, see *diet*; nutrition as therapy, 81-85; overweight, see *obesity*, *overweight*; post-HSCT nutritional issues, 91; supplemental nutrition, 83-85, 91, 95; underweight, see *underweight*
 obesity, 74, 85-86, 93, 97, 150-151, 154, 156, 174, overweight, 85-86; diet,

- see *diet*; eating disorder, 86; glucocorticoids and anticonvulsant therapy, effect on, 170; metabolic syndrome, see *metabolic syndrome*; nutrition, see *nutrition*; over-the-counter weight loss preparations, 88; sleep disorder or snoring related to, 86
- odynophagia, 210, 275
- oral cavity, 203, 209, 248, 271-273, 275, 278, 283, 293, 389, 391, see also *head and neck squamous cell carcinoma*
- oral dryness, 137, 233, 246, 248, 279, 282; pain, 210, 214- 215
- oropharynx, 210, 251, 272, 275, 284, 298, see also *head and neck squamous cell carcinoma*
- osteopenia, 165, 250, 375, 390, osteoporosis, 56, 131-132, 135, 144, 165, 168, 170, 177, 250, 375, 380-381, 386, 390; bone mineral density, 132, 141, 144, 149-150, 152, 165-168, 172, 178, 370; bone therapy, 166-167; dual energy absorptiometry (DXA) scan, 166, 375; Z-score, 165
- ova and parasites, 79
- ovarian, 7-8, 22, 128, 131-132, 135, 141, 163-164, 167, 169, 177, 299, 308, 319, 322-323, 330-332, 387; failure, 131-132, 136, 164, 167; function, 169-170, effect of anticonvulsant therapy on, 170; tissue cryopreservation, 131, 164
- oxidative stress, 94, 239, 266, 390
- oxymetholone, 56-58, 69
- pain, abdominal, 74, 78-79, 81, 91; eye pain, with GvHD, 238; gastroesophageal reflux or tracheoesophageal fistula, pain from, 76-77; intestinal stricture, pain with, 77; oral, with GvHD, 233; sedation and analgesia for invasive procedures, 63 189, 299, 364
- pancreas, 62, 91-92; pancreatic beta cell dysfunction, 153, 170-171; pancreatic insufficiency, 91
- pancytopenia, 72
- penis, 162, 164
- peptic disorders, see *gastrointestinal*
- phalanx, 18, 109-110, 392
- pituitary, 62, 144, 148, 157, 159, 161-162, 169, 171, 173, 175-176, 387
- platelets, 45, 53, 57-58, 60, 67, 88, 95, 129, 224, 226, 241, 262, 364, 384, 390

- pneumonia, 77, 249
- polydactyly, 109-110, 121, 391, pre-axial, 109-110, 391
- polypharmacy, 371, 391, 414, 417
- potassium, 234
- pregnancy, 13-14, 45, 76, 124, 129-130, 141, 164, 176, 250, 257, 307, 312, 318, 323-325, 353, 379; amniocentesis, 18, 324, 371; androgen use during, 129; discuss childbearing options pre-transplant, 129-130; complications, 130; reproductive options and family planning, 323
- preimplantation genetic diagnosis (PGD), 2-3, 13, 33, 221, 241, 311, 323-326, 332, 337-338, 371, 390
- psychosocial issues, 248, 296, 302, 333, 343; high-risk behaviors, 274, 302; recommendations for the physician, 349
- puberty, 123-124, 139, 144, 147, 159, 162-163, 170, 173, 274, 377, 379; breast buds, 123-124; delay, 124, 162-163; early onset, 162; relation to transplant, 147, 149, 169; treatment benefits for bone mineralization, 165-167
- pulmonary, 223, 237, 249, 253, 374, complications, 223, 374, post-transplant, 223, 274; function, 249, 253
- quality of life, 49, 61, 132, 160, 167, 215, 237, 245, 251, 258, 261, 303, 341, 363, 376, 381
- radial ray, 20, 377; abnormalities, 20, 377; carpectomy, 117; centralization, 115-117, 119; classification of radial deficiency, 111-112; external fixator, 117, 119; radial deviation of the hand, 111, 116-119; splint, 115-116, 118; stretching, 114, 115
- radiation, sensitivity to, 79; non-radiation imaging techniques, 79; pediatric and adult CT protocols, 79; total body irradiation, risks of, 14, 57-58, 60-62, 64, 73, 90, 92-94, 130, 162, 174, 177, 192, 201, 216, 223, 228-229, 238, 241, 269, 296, 299, 375, 381, 392
- reactive airway disease, 228
- red cells, 17, 53, 57-58, 62, 64, 384, androgen effect on, 53; iron overload, 62; macrocytosis, 44-45; transfusions of, 57-58; transfusions for uterine bleeding, 133
- reflux, 77, 80, 84, 167, 226, 369; esophageal, 167; gastroesophageal (GER), 77, 80, 84, 226; ureteral, 226
- renal system, anomalies, 76, 101, 102, 226, 246, 369, 370, 379;

hydronephrosis, 19, 369; hydroureter, 19; toxicity 94-95

ribs, 189

scaphoid, 114

school, education, 184-186, 302, 341-342, 381

scoliosis, 250, 257

seizures, 130, 232-233

Self Help for Hard of Hearing People, 193

Sertoli cell mass, 164

serum C-reactive protein, 79

sexually transmitted diseases, 124-125, 136, 274

short stature, see *height*

siblings of FA patients, 3-4, 30, 33-34, 44, 58, 191, 227, 302, 313, 317, 324, 332-333, 337-339, 342, 347, 351, 355, 367, 372; genotype/phenotype correlations between FA siblings, 33, 313-317; onset of bone marrow failure between FA siblings, 44, 372; psychosocial demands on, 4, 335, 337-339; psychosocial functioning of FA patients compared to healthy siblings, 355-356; test to rule out FA in, 30, 191, 367

sinuses, 228, sinusitis, 248

skeletal anomalies, 99

skin, see *dermatology*

smoking, cannabis (marijuana) 274; cigarettes, 298; second-hand smoke, 251, 271-272, 274, 283, 378

speech and language therapy, 186, 376

squamous cell carcinoma, see *cancer* or specific type of cancer

St. John's wort, 228

stroke, 73, 131

Sweet's syndrome, see *dermatology*

testes, 144, 162-164, 167, 382

thalassemia, 62-64, 73

thrombocytopenia, 43, 45, 57, 64, 67, 88, 129-130, 133, 141-142, 392

thumb, abnormalities of, 114; duplicated thumbs, 110; hypoplastic, floating

- (*pouce flottant*) or absent, 99, 103-104; opponensplasty, 104; pollicization, 104; triphalangeal, 19, 109-110
- thyroid, 62, 133, 144, 147, 156-158, 167, 169, 171-173, 177-178, 206, 208, 221, 250, 370, 381, 388; effect of anticonvulsant therapy or metaclopramide on, 170; hypoparathyroidism, 63, 169; hypothyroidism, 63, 124, 133, 144-147, 149, 156-158, 161-162, 167, 169-171, 246, 250, 374, 377, 388; post-HSCT, function, 169-170
- thyroxine-binding globulin (TBG, T4, FT4), 149, 156-58, 167, 253-54
- tobacco use, see *smoking*
- tracheoesophageal fistula, 75-76, 226, 392
- transaminitis, 249
- transfusions, effect on iron load, 62-66, 90, 92-94, 169, 238, 375, 381; family members as donors, 62, 375; for abnormal uterine bleeding, 133; HLA-typing and donor search before need for, 51, 58-59; menstrual suppression to decrease risk for transfusion prior to transplant, 133-135; platelet transfusions, 67; pregnancy, transfusions related to, 130
- transplant, 4, 13, 17-18, 47-48, 51-53, 57-62, 64, 67, 71, 74, 91, 98, 123, 129, 133-134, 141, 147, 149, 176-178, 199, 201, 220, 222-230, 235-242, 244-245, 247, 251-252, 255, 257-258, 262-264, 291, 295-297, 299-300, 325, 334, 337-339, 342, 346-347, 354-355, 358, 362, 364-366, 372-373, 375-376, 379-381, 383-389
- transplant, androgen use prior to, see *androgens*
- transplant, effect of clonal abnormalities, see *clones, cytogenetic clonal abnormalities*
- transplant, fertility, 123, 129, 135, 164, 231, 246, 373, 379
- transplant, grafts, 71, 106, 242; graft failure, 221-223, 236-237
- transplant, graft-versus-host disease (GvHD), 18, 53, 19, 55, 64, 91-92, 94, 101, 128, 136, 142, 181, 196, 200-202, 204, 206-207, 220, 222-223, 228, 232-233, 235-237, 240, 246-251, 255-256, 263-264, 271, 273, 283, 296-297, 299, 311, 380, 386-387; acute, 233; chronic, 233; concurrent medication, effect on, 227-228; immunosuppression, 232; infection risk, 235, 237, 251; ocular complications, see *vision*; prophylaxis, 235; risk of carcinoma from, 221-222, 237-238
- transplant, hematopoietic stem cell, 52-53, 60, 62, 64, 74, 91, 123, 141, 149, 219-255, 262, 376, see individual topics below

- transplant, immunizations post-transplant, see *vaccinations, immunizations*
- transplant, immunosuppression, 201, 220, 222, 232-233, 235, and immune reconstitution, 258
- transplant, late effects, 244-245; endocrine, 246, 250, 253; growth and development, 248, 254; hematology, 250, 252, 254; immunology, 251-252; malignancy risk, 251; metabolic syndrome, see *metabolic syndrome*; ocular complications, 248, see also *vision*; quality of life, 251
- transplant, matched sibling donor, 221-222; androgen and cytokine therapy prior to transplant, 238-239; cytoreductive regimens, overview and results of, 221-222
- transplant, organ function, effect on transplant, 246, 248-251
- transplant, post-transplant: long-term follow-up, 244-255
- transplant, radiation, 221-223; preparative regimen without radiation, 223
- transplant, selection of transplant center, 224-226, 373
- transplant, stem cell source, marrow, 219, 228-229; peripheral blood, 11, 14, 20, 28-29, 31-32, 39-40, 45-46, 48-51, 53, 133, 191, 223, 228, 230, 237, 240; umbilical cord blood, 222, 240-241, 323, 325, 390, 392
- transplant, transfusions prior to, see *transfusions*
- transplant, unrelated donor, 52, 59-61, 221-223, 228-229, 238, 372-373; alternatives to, 220, 223, 238-239, 336; donor search, insurance company approval, 51, 225-226, 229; donor search, selection, and timing of process, 59-60, 228-230, 373; eligibility for transplant, 226-230; indications for, 223-224; infection post-transplant, 251, 374; infectious disease prophylaxis, 235; initial assessment at transplant center, 224-227
- transposons, 264
- tumor, see *cancer* or specific type of cancer
- ulna, 111, 113, 115-119, 384; in centralization, 115-119; lengthening of, 111, 119-120
- underweight, 82, 86, 147-158; appetite stimulants, 85, 88, 96, 99; assessment of growth, 147-153; delayed gastric emptying, effect on, 77-78, 80-81, 85; duodenal atresia or stenosis, effect on, 75, 77; malabsorption, effect on, 82-83; medical causes of, 82-83; nutrition, see *nutrition*; nutritional causes of, 147-158; poor oral intake, 82-83; supplemental nutrition for, 83-85

- urinary tract, 75, 77-78, 369, 382; congenital anomalies, 16, 118, 250; ureteral reflux, 226
- uterus, 133-135, 164, 240-241, 389-390; menstrual bleeding, 123, 129, 133-135
- vaccinations, 125, 226, 251, immunizations, 226, 251-252, 374; hepatitis A and B, 90; HPV, 18, 124-127, 136, 238, 249, 251-252, 274, 298, 378-379, 381; post-transplant, 251-252, 374; influenza, 251, 374
- VACTERL, 75-76, 99, 101-102, 367; VACTERL-H, 20, 33, 101
- vaginal, 16, 125, 131-132, 138, 142-143, 379; dryness, 131-132, 138, 143
- virus, viral, see *infections*
- vision, 64, 248; cataracts, 19, 232, 234, 246, 248, 374, 381; keratoconjunctivitis sicca syndrome, 248; ocular complications post-transplant, 374; strabismus, 19; vision loss, side effect of deferoxamine, 64-65
- vitamins, 83, 90, 92-95, 226, minerals, 83, 390, and herbal remedies, 226; antioxidants, 93-94; calcium, 149, 151, 166, 254; fat-soluble vitamin levels, 90, 92; folate, 83; fortified fruit juice or other beverages, 92; magnesium, 166, 280; potassium, 234; supplements, 67, 83, 94-95, 151, 196, 200, 226, 228, 372; vitamin C, 93-95; vitamin D, 83, 149-151, 166, 196, 200, 250, 254; vitamins A and E, 92, 95, cancer risks of, 94; vitamins, effect of cholestasis on, 92; zinc, 83
- vomiting, 77, 84, 134
- vulvar cancer, see *gynecologic and fertility issues in females*
- weight, see *obesity, overweight; underweight; diet; nutrition; wheezing, 77*
- Wilms tumor, 16
- wrist, fusion, 119-120; radial deviation, 111, 113-119
- x-linked inheritance, 25, see also *genetic counseling*